EAGER: Device for Prevention of Endotracheal Tube Biofilm Formation for the Prevention of Ventilator Associated Pneumonia

EAGER：预防气管插管生物膜形成的装置，用于预防呼吸机相关肺炎

• 批准号: 2033628
• 负责人: Eric Seibel
• 金额: $ 25.02万
• 依托单位: University of Washington
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2033628&HistoricalAwards=false
• 关键词: EAGER; Device; Prevention; Endotracheal; Tube

Intellectual Merit: There is an increased need for ventilators for patients suffering from the current SARS-CoV-2 pandemic. This project aims to reduce the burden of ventilator associated pneumonia on hospitals that will lead to an overall reduction in the length of required mechanical ventilation. VAP is a worldwide problem that penetrates all echelons of intensive care units throughout the world, and biofilms are regarded as a significant source of this persistent problem. This research project proposes to build and investigate a novel device for the prevention of VAP by reducing or eliminating the burden of biofilm formation on the inside of endotracheal tubes (ETT). The proposed device has the potential to destroy bacteria before they have a chance to form biofilms on the inner lumen of endotracheal tubes), reducing the incidence of this significant burden on healthcare systems across the globe in a practical and cost efficient manner. Specifically, the device will be used to reduce colonization and biofilm formation on the inner lumen of ETTs by regular application of deep ultraviolet (UVC) radiation via a thin catheter to be fed down the ETT. This portable handheld device would be used by respiratory therapists and/or bedside nurses as part of routine care of mechanically ventilated patients. Short wavelength UVC would not penetrate out and through the ETT, thus sparing the oropharyngeal and respiratory mucosa from radiation exposure. Broader Impact:The risk of developing VAP is 2-16 per 1,000 ventilator-days, and a diagnosis of VAP has been associated with an additional cost of $40,000 per patient. If the proposed device reduces the burden of VAP, its adoption into regular ICU care could save thousands of lives and billions of dollars per year. The proposed research will further the body of knowledge on the timeline by which biofilms form inside ETTs and will also contribute to our knowledge of antibiotic-free decontamination strategies, especially those for use at the bedside of critically ill patients. Additionally, the research will contribute strongly to the present body of knowledge on diffuse UVC radiation and its safety for use inside standard ETTs in healthy humans. This work will also contribute to the knowledge of antibiotic-free decontamination strategies, especially those for use at the bedside of critically ill patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

智力优势：当前 SARS-CoV-2 大流行的患者对呼吸机的需求不断增加。该项目旨在减轻医院呼吸机相关肺炎的负担，从而总体减少所需机械通气的时间。 VAP 是一个世界性问题，渗透到全世界重症监护室的各个层级，而生物膜被认为是这一持续问题的重要根源。该研究项目旨在构建和研究一种新型装置，通过减少或消除气管插管 (ETT) 内部生物膜形成的负担来预防 VAP。 所提出的装置有可能在细菌有机会在气管插管内腔形成生物膜之前将其消灭，从而以实用且具有成本效益的方式减少对全球医疗保健系统造成的这一重大负担的发生率。具体来说，该设备将用于通过细导管定期应用深紫外 (UVC) 辐射来减少 ETT 内腔的定植和生物膜形成，并将其送入 ETT。这种便携式手持设备将由呼吸治疗师和/或床边护士使用，作为机械通气患者日常护理的一部分。短波长 UVC 不会穿透 ETT，从而使口咽和呼吸道粘膜免受辐射照射。更广泛的影响：每 1,000 个呼吸机日发生 VAP 的风险为 2-16 个，诊断 VAP 与每位患者 40,000 美元的额外费用相关。如果拟议的设备减轻 VAP 的负担，将其纳入常规 ICU 护理中每年可以挽救数千人的生命并节省数十亿美元。拟议的研究将进一步加深对 ETT 内生物膜形成时间线的了解，也将有助于我们了解无抗生素净化策略，特别是在危重患者床边使用的策略。此外，该研究还将为目前关于扩散 UVC 辐射及其在健康人类标准 ETT 内使用的安全性的知识体系做出巨大贡献。这项工作还将有助于了解无抗生素净化策略，特别是那些在危重患者床边使用的策略。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响进行评估，被认为值得支持审查标准。